2016 Macula Society 39th Annual Meeting

Miami, FL US
February 24, 2016 to February 27, 2016

This educational activity is designed to improve patient care and to promote innovative research to push the field forward through reporting of the latest findings from multi-center clinical trials, discussion of investigator initiated studies, and the sharing of the cutting-edge research findings among the Macula Society members and guests.

The Macula Society was founded in 1977 as a society for vitreoretinal physicians, surgeons and researchers to gather, learn, and discuss the new frontiers in retinal surgery, clinical care and treatment and research studies. Annual meetings of the Macula Society provide a forum for reporting on the most innovative research, clinical experience and the latest clinical trial findings in the areas of retinal, macular and vitreous diseases and surgery, and for spirited discussions about new and possibly controversial treatment modalities.


ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical College of Wisconsin and The Macula Society. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live Activity for a maximum of 19.50 AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 19.50 hours of participation for continuing education for allied health professionals.
This meeting was supported by an unrestricted educational grant from:  Alcon Research, Alimera Sciences, Bausch & Lomb, Bayer Healthcare, Carl Zeiss Meditec, Heidelberg Engineering, InFocus Clinical, Mallinckrodt Pharmaceutical, Forsee/Notal Vision, Ohr Pharmaceutical, Optos, Inc. Optovue, Inc. Santen Inc., Second Sight Medical Product, Spark Therapeutics, ThromboGenics, TopCon Medical Systems.



Target Audience

Vitreoretinal specialists and surgeons-members of the Society; and Co-authors who are researchers, fellows, and ophthalmologists

Learning Objectives

At the conclusion of this activity, I will be able to:
  1. Discuss findings from recently completed multi-center clinical trials in retina
  2. Appraise the efficacy and safety results for clinical studies investigating available and emerging treatment options and treatment modalities for macular diseases
  3. Implement best practices for these disease states based upon an evaluation of clinical trials, investigator initiated studies, and diagnostic and imaging technologies
Additional information


Stacy Singerman
Phone Number: 
+1 (216) 839-4949
Course summary
Available credit: 
  • 19.50 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 19.50 Hours of Participation
    Hours of Participation credit.
Course opens: 
Course expires: 
Event starts: 
02/24/2016 - 2:30pm CST
Event ends: 
02/27/2016 - 1:00pm CST
Eden Roc Resort Hotel
4525 Collins Avenue
Miami, FL 33140
United States
Program Committee
Judy E. Kim, MD Chair
Caroline R. Baumal, MD
R.V. Paul Chan, MD, MSc, FACS
Craig M. Greven, MD
Jennifer I. Lim, MD
Lawrence J. Singerman, MD
M. Gilbert Grand, MD
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships.  These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

Available Credit

  • 19.50 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 19.50 Hours of Participation
    Hours of Participation credit.


Please login or register to take this course.